Cargando…

Genetic determinants of the humoral immune response in MS

OBJECTIVE: In this observational study, we investigated the impact of genetic factors at the immunoglobulin heavy chain constant locus on chromosome 14 and the major histocompatibility complex region on intrathecal immunoglobulin G, A, and M levels as well as on B cells and plasmablasts in the CSF a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gasperi, Christiane, Andlauer, Till F.M., Keating, Ana, Knier, Benjamin, Klein, Ana, Pernpeintner, Verena, Lichtner, Peter, Gold, Ralf, Zipp, Frauke, Then Bergh, Florian, Stangel, Martin, Tumani, Hayrettin, Wildemann, Brigitte, Wiendl, Heinz, Bayas, Antonios, Kümpfel, Tania, Zettl, Uwe K., Linker, Ralf A., Ziemann, Ulf, Knop, Matthias, Warnke, Clemens, Friese, Manuel A., Paul, Friedemann, Tackenberg, Björn, Berthele, Achim, Hemmer, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371373/ https://www.ncbi.nlm.nih.gov/pubmed/32675288 http://dx.doi.org/10.1212/NXI.0000000000000827

Ejemplares similares

Is APOE ε4 associated with cognitive performance in early MS?
por: Engel, Sinah, et al.
Publicado: (2020)

Treatment choices and neuropsychological symptoms of a large cohort of early MS
por: von Bismarck, Olga, et al.
Publicado: (2018)

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
por: Bittner, Stefan, et al.
Publicado: (2020)

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders
por: Bayas, A., et al.
Publicado: (2021)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
por: Ostkamp, Patrick, et al.
Publicado: (2021)

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS)
por: Johnen, Andreas, et al.
Publicado: (2018)

Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose
por: Wiendl, Heinz, et al.
Publicado: (2021)

Association of obesity with disease outcome in multiple sclerosis
por: Lutfullin, Isabel, et al.
Publicado: (2023)

Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort
por: Salmen, Anke, et al.
Publicado: (2023)

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis
por: Abrahamyan, Sargis, et al.
Publicado: (2020)

Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devices—A Critical Appraisal
por: Wick, Manfred, et al.
Publicado: (2021)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation
por: Andlauer, Till F. M., et al.
Publicado: (2016)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions
por: Wiendl, Heinz, et al.
Publicado: (2021)

The choline pathway as a strategy to promote central nervous system (CNS) remyelination
por: Skripuletz, Thomas, et al.
Publicado: (2015)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage
por: Linker, Ralf A., et al.
Publicado: (2009)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
por: Rau, Daniela, et al.
Publicado: (2015)

Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study
por: Abdelhak, Ahmed, et al.
Publicado: (2020)

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
por: Gold, Ralf, et al.
Publicado: (2021)

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
por: Kemmerer, C. L., et al.
Publicado: (2020)

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
por: Jarius, Sven, et al.
Publicado: (2012)

Neurochemical Biomarkers in patients with COVID-19
por: Tumani, Hayrettin
Publicado: (2023)

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway
por: Luo, Yi, et al.
Publicado: (2021)

CSF parameters associated with early MRI activity in patients with MS
por: Klein, Ana, et al.
Publicado: (2019)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders
por: Aly, Lilian, et al.
Publicado: (2021)

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms
por: Neumann, Bernhard, et al.
Publicado: (2020)

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
por: Lehmann-Horn, Klaus, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_uiu9gn25t9me95behb299qllo0